Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 160 million infections and more than 3 million deaths worldwide. Although effective vaccines are currently being deployed, the adaptive immune determinants that promote viral clearance and confer protection remain poorly defined. Using mouse models of SARS-CoV-2, we demonstrate that both humoral and cellular adaptive immunity contribute to viral clearance in the setting of primary infection. Furthermore, we find that either convalescent mice or mice that receive mRNA vaccination are protected from both homologous infection and infection with a variant of concern, B.1.351. In addition, we find that this protection is largely mediated by antibody response and not cellular immunity. These results highlight the in vivo protective capacity of antibodies generated to both vaccine and natural infection.
【초록키워드】 severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, mRNA vaccination, Vaccine, coronavirus, adaptive, Immunity, antibody, B.1.351, Antibody Response, variant, Infection, severe acute respiratory syndrome Coronavirus, viral clearance, immune, cellular immunity, mice, death, convalescent, Mouse models, in vivo, mouse model, natural infection, homologous, Protective, Primary infection, cellular, humoral, determinant, acute respiratory syndrome, acute respiratory syndrome coronavirus, Effective vaccines, highlight, defined, caused, addition, contribute, promote, effective vaccine, receive, 【제목키워드】 SARS-CoV-2, immune, mouse model, determinant,